Skip to main content
SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD logo

SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002737 ISIN · CNE100001WT7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,264 across all filing types
Latest filing 2017-07-12 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002737

About SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD

https://www.kuihuayaoye.com

Sunflower Pharmaceutical Group Co., Ltd. focuses on the research, development, manufacturing, and distribution of proprietary Chinese medicines, chemical drugs, and health supplements. The organization is particularly noted for its specialization in pediatric medicine, marketed under the "Little Sunflower" brand, which includes treatments for respiratory and digestive ailments. Its extensive product portfolio also covers gynecological health and general internal medicine. The group operates several integrated production bases and research institutes, facilitating a comprehensive approach to drug formulation and quality control. By leveraging a robust supply chain and a wide-reaching distribution network, the company provides a diverse range of over-the-counter and prescription solutions aimed at improving family health and wellness.

Recent filings

Filing Released Lang Actions
关于共同控制关系解除的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the change in the company's actual control due to the divorce and subsequent shareholding reallocation between two individuals who were joint controllers. It details the transfer of shares and control rights, legal notarization, and the resulting change in the company's controlling shareholder. There are no financial statements, earnings data, or detailed management discussion. The document is a regulatory announcement about changes in control and shareholding structure, not a financial report or meeting material. Therefore, it fits best under Regulatory Filings (RNS). The document length is short (2586 characters), and it is a formal announcement of a corporate event affecting control, not a report or presentation.
2017-07-12 Chinese
详式权益变动报告书（二）
Regulatory Filings
2017-07-12 Chinese
关于公司实际控制人股权质押公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding the pledge of shares by the company's actual controller, including details about the number of shares pledged, pledge dates, pledgee, and the impact on control. It does not contain financial statements, audit information, or management discussion. It is a regulatory announcement about share pledge activity by a major shareholder. This fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories like Major Shareholding Notification (MRQ) because it concerns share pledge, not ownership threshold changes.
2017-07-11 Chinese
关于控股子公司葵花药业集团（重庆）有限公司更名公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the name change of a controlling subsidiary, including details about the new business license and registration information. It is a formal disclosure by the board of directors but does not contain financial data, audit information, or any report content. It is not a report or financial filing but a regulatory announcement about corporate structure/name change. This fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2017-06-26 Chinese
关于公司控股股东葵花集团有限公司领取新版营业执照公告
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding the receipt of a new business license by the company's controlling shareholder. It contains no financial data, no report or presentation, and no voting or management changes. It is a regulatory announcement about a corporate administrative update. The document length is only 553 characters, indicating it is a brief notice rather than a full report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2017-06-14 Chinese
关于公司使用自有资金收购控股子公司葵花药业集团（襄阳）隆中有限公司10%股权的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's use of its own funds to acquire a 10% equity stake in its controlling subsidiary. It details the transaction overview, approval procedures, basic information about the target company and counterparty, funding source, pricing basis, main terms of the transaction agreement, independent director opinions, and the purpose and impact of the acquisition. The document includes financial data of the subsidiary but does not present a full financial report or comprehensive financial statements for the company itself. It is a disclosure about a capital transaction involving share acquisition within the group. This fits the definition of a Capital/Financing Update (CAP) as it relates to company fundraising or capital structure changes. The document length is under 5,000 characters, but it contains substantive transaction details rather than just announcing a report publication, so it is not an RPA. Therefore, the correct classification is CAP with high confidence.
2017-06-13 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.